- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Vinca Alkaloid.
Displaying page 1 of 1.
EudraCT Number: 2009-011118-47 | Sponsor Protocol Number: L00070IN308B0 | Start Date*: 2009-04-24 | |||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT | |||||||||||||
Full Title: Phase III trial of IV vinflunine versus an alkylating agent in patients with metastatic breast cancer previously treated with or resistant to an anthracycline, a taxane, an antimetabolite, and a vi... | |||||||||||||
Medical condition: Metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) PT (Completed) IT (Completed) ES (Completed) BE (Completed) DE (Completed) AT (Completed) HU (Completed) GB (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003216-30 | Sponsor Protocol Number: 309544 | Start Date*: 2005-11-14 |
Sponsor Name:Schering AG | ||
Full Title: Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy, safety and tolerability of 4 regimes with 3 doses of ZK 219477 (16 and 12 mg/m² body ... | ||
Medical condition: Histologically proven metastatic breast cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Completed) AT (Completed) ES (Completed) SI (Completed) IT (Completed) BE (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-001508-38 | Sponsor Protocol Number: ST 200-DM-03-005 | Start Date*: 2006-03-21 | |||||||||||
Sponsor Name:SIGMA-TAU | |||||||||||||
Full Title: Phase II Explorative Study of Acetyl-L-Carnitine (ST 200) for Vincristine-Induced Neurotoxicity in Patients With Acute Lymphoblastic Leukemia (ALL). | |||||||||||||
Medical condition: Treatment of peripheral sensitive neuropathy vinca alkaloid chemotherapy -induced. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016879-29 | Sponsor Protocol Number: IPR/22 | Start Date*: 2010-01-25 | |||||||||||
Sponsor Name:MOLMED | |||||||||||||
Full Title: NGR015: Randomized double-blind phase III study of NGR-hTNF plus best investigator s choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma... | |||||||||||||
Medical condition: Patients with advanced malignant pleural mesothelioma (MPM)previously treated with pemetrexed | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) AT (Completed) IE (Completed) GB (Completed) NL (Completed) BE (Completed) SE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010004-28 | Sponsor Protocol Number: ACNS0331 | Start Date*: 2010-04-14 | ||||||||||||||||
Sponsor Name:COG | ||||||||||||||||||
Full Title: ACNS0331 A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblas... | ||||||||||||||||||
Medical condition: Medulloblastoom standard risk | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-002286-32 | Sponsor Protocol Number: 6125 | Start Date*: 2009-08-10 | ||||||||||||||||
Sponsor Name:Queen Mary Medical University of London | ||||||||||||||||||
Full Title: Phase I/II Study combining humanised anti-CD20 (veltuzumab), anti-CD22 (epratuzumab) and both monoclonal antibodies with chemotherapy in adults with recurrent B precursor acute lymphoblastic leukae... | ||||||||||||||||||
Medical condition: This is a phase I/ II trial to determine the efficacy of intravenous veltuzumab and epratuzmab either individually or together in combination with chemotherapy in patients with recurrent acute lymp... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-003232-24 | Sponsor Protocol Number: AVA-PED-301 | Start Date*: 2020-12-03 | ||||||||||||||||||||||||||
Sponsor Name:Dova Pharmaceuticals, Inc. | ||||||||||||||||||||||||||||
Full Title: A Phase 3b, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment... | ||||||||||||||||||||||||||||
Medical condition: Thrombocytopenia in paediatric subjects with immune thrombocytopenia for ≥6 months duration who have had an insufficient response to a previous treatment | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FR (Completed) HU (Ongoing) DE (Ongoing) PL (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.